Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Molecular Diagnostic Techniques | 9 | 2020 | 47 | 3.070 |
Why?
|
Polymerase Chain Reaction | 20 | 2020 | 492 | 2.840 |
Why?
|
RNA, Viral | 14 | 2014 | 93 | 1.690 |
Why?
|
HIV-1 | 8 | 2020 | 177 | 1.600 |
Why?
|
Blood Culture | 3 | 2020 | 15 | 1.440 |
Why?
|
Virology | 6 | 2011 | 11 | 1.420 |
Why?
|
Bacteremia | 5 | 2020 | 155 | 1.410 |
Why?
|
Enterovirus Infections | 4 | 2011 | 6 | 1.340 |
Why?
|
Hepacivirus | 9 | 2005 | 90 | 1.270 |
Why?
|
Microbial Sensitivity Tests | 12 | 2021 | 226 | 1.140 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 7 | 2011 | 710 | 1.100 |
Why?
|
Enterovirus | 4 | 2017 | 12 | 1.090 |
Why?
|
Meningitis, Viral | 3 | 2011 | 5 | 1.060 |
Why?
|
Nucleic Acid Amplification Techniques | 5 | 2014 | 21 | 1.000 |
Why?
|
Virus Diseases | 4 | 2014 | 31 | 0.960 |
Why?
|
Sensitivity and Specificity | 24 | 2022 | 1753 | 0.950 |
Why?
|
Anti-Bacterial Agents | 11 | 2018 | 1026 | 0.890 |
Why?
|
Viral Load | 9 | 2014 | 127 | 0.880 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2021 | 209 | 0.840 |
Why?
|
Pathology, Molecular | 1 | 2020 | 5 | 0.730 |
Why?
|
Humans | 88 | 2022 | 68618 | 0.710 |
Why?
|
Pandemics | 2 | 2022 | 352 | 0.710 |
Why?
|
Respiratory Tract Infections | 5 | 2018 | 91 | 0.700 |
Why?
|
Bacteriological Techniques | 5 | 2013 | 49 | 0.670 |
Why?
|
Betacoronavirus | 1 | 2020 | 116 | 0.650 |
Why?
|
HIV Infections | 5 | 2020 | 791 | 0.640 |
Why?
|
Diarrhea | 3 | 2013 | 63 | 0.630 |
Why?
|
Reagent Kits, Diagnostic | 4 | 2008 | 54 | 0.620 |
Why?
|
Drug Utilization | 2 | 2016 | 119 | 0.610 |
Why?
|
Coronavirus Infections | 1 | 2020 | 143 | 0.580 |
Why?
|
Feces | 4 | 2013 | 88 | 0.580 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 154 | 0.580 |
Why?
|
Legionella | 5 | 2012 | 9 | 0.570 |
Why?
|
Legionnaires' Disease | 4 | 2012 | 11 | 0.570 |
Why?
|
Microbiological Techniques | 3 | 2012 | 9 | 0.570 |
Why?
|
Influenza B virus | 1 | 2016 | 2 | 0.560 |
Why?
|
Candidemia | 1 | 2016 | 2 | 0.560 |
Why?
|
Influenza A virus | 1 | 2016 | 13 | 0.560 |
Why?
|
Mutation | 2 | 2016 | 1213 | 0.550 |
Why?
|
Myelodysplastic Syndromes | 1 | 2016 | 24 | 0.540 |
Why?
|
Thalidomide | 1 | 2016 | 24 | 0.540 |
Why?
|
Communicable Diseases | 2 | 2012 | 50 | 0.540 |
Why?
|
Viruses | 4 | 2009 | 14 | 0.530 |
Why?
|
Bacterial Infections | 3 | 2018 | 163 | 0.530 |
Why?
|
Influenza, Human | 1 | 2016 | 79 | 0.520 |
Why?
|
Immunologic Factors | 1 | 2016 | 87 | 0.510 |
Why?
|
Point-of-Care Systems | 1 | 2016 | 115 | 0.500 |
Why?
|
Tuberculosis, Pulmonary | 3 | 2006 | 61 | 0.490 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2014 | 44 | 0.480 |
Why?
|
Alphapapillomavirus | 1 | 2014 | 17 | 0.480 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.480 |
Why?
|
Aged, 80 and over | 10 | 2020 | 4848 | 0.460 |
Why?
|
HIV Antibodies | 2 | 2010 | 28 | 0.450 |
Why?
|
Leukorrhea | 1 | 2013 | 6 | 0.450 |
Why?
|
DNA, Viral | 4 | 2017 | 114 | 0.450 |
Why?
|
Trichomonas vaginalis | 1 | 2013 | 22 | 0.440 |
Why?
|
Trichomonas Vaginitis | 1 | 2013 | 25 | 0.430 |
Why?
|
HIV Seropositivity | 2 | 2010 | 66 | 0.430 |
Why?
|
Clostridium Infections | 1 | 2013 | 52 | 0.430 |
Why?
|
Transplantation | 1 | 2012 | 23 | 0.420 |
Why?
|
Hepatitis C | 5 | 2005 | 114 | 0.420 |
Why?
|
Pathologists | 3 | 2021 | 10 | 0.420 |
Why?
|
Diagnostic Services | 1 | 2012 | 1 | 0.410 |
Why?
|
Penicillin Resistance | 3 | 2005 | 12 | 0.410 |
Why?
|
Adult | 24 | 2020 | 21403 | 0.400 |
Why?
|
Papillomavirus Infections | 1 | 2014 | 194 | 0.400 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 300 | 0.390 |
Why?
|
Herpesvirus 4, Human | 2 | 2008 | 30 | 0.390 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2008 | 24 | 0.390 |
Why?
|
Reproducibility of Results | 8 | 2021 | 2077 | 0.390 |
Why?
|
AIDS Vaccines | 1 | 2010 | 7 | 0.370 |
Why?
|
Hepatitis C, Chronic | 2 | 2003 | 86 | 0.370 |
Why?
|
Middle Aged | 18 | 2020 | 21147 | 0.370 |
Why?
|
Young Adult | 9 | 2020 | 5717 | 0.360 |
Why?
|
Aged | 13 | 2020 | 14862 | 0.350 |
Why?
|
Culture Media | 6 | 1995 | 155 | 0.340 |
Why?
|
Oxacillin | 2 | 2005 | 4 | 0.330 |
Why?
|
Female | 24 | 2017 | 38074 | 0.330 |
Why?
|
Klebsiella pneumoniae | 1 | 2008 | 18 | 0.330 |
Why?
|
beta-Lactamases | 1 | 2008 | 33 | 0.320 |
Why?
|
Infant, Newborn | 6 | 2020 | 2455 | 0.310 |
Why?
|
Bacterial Proteins | 2 | 2008 | 245 | 0.310 |
Why?
|
Staphylococcus aureus | 2 | 2005 | 175 | 0.300 |
Why?
|
Pneumonia | 1 | 2008 | 110 | 0.300 |
Why?
|
Clinical Laboratory Techniques | 4 | 2008 | 60 | 0.290 |
Why?
|
5' Untranslated Regions | 2 | 2007 | 16 | 0.290 |
Why?
|
Adolescent | 8 | 2020 | 8912 | 0.280 |
Why?
|
Polyomavirus Infections | 1 | 2006 | 17 | 0.280 |
Why?
|
Sequence Analysis, DNA | 4 | 2012 | 208 | 0.280 |
Why?
|
Tumor Virus Infections | 1 | 2006 | 32 | 0.280 |
Why?
|
Viremia | 5 | 1999 | 13 | 0.270 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 11 | 0.270 |
Why?
|
Male | 25 | 2017 | 37321 | 0.270 |
Why?
|
Time Factors | 8 | 2016 | 4655 | 0.270 |
Why?
|
DNA Mutational Analysis | 1 | 2006 | 159 | 0.260 |
Why?
|
Penicillin-Binding Proteins | 1 | 2005 | 15 | 0.260 |
Why?
|
Infant | 6 | 2017 | 2891 | 0.260 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 1997 | 116 | 0.260 |
Why?
|
Blood | 3 | 2007 | 40 | 0.250 |
Why?
|
Child, Preschool | 6 | 2017 | 3187 | 0.250 |
Why?
|
Bone Marrow Transplantation | 2 | 1996 | 149 | 0.250 |
Why?
|
False Positive Reactions | 4 | 2014 | 95 | 0.250 |
Why?
|
Beauty Culture | 1 | 2004 | 1 | 0.240 |
Why?
|
Furunculosis | 1 | 2004 | 1 | 0.240 |
Why?
|
Nails | 1 | 2004 | 15 | 0.240 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2004 | 2 | 0.240 |
Why?
|
Mycobacterium | 1 | 2004 | 12 | 0.240 |
Why?
|
Nucleic Acid Hybridization | 3 | 2003 | 95 | 0.240 |
Why?
|
Genotype | 5 | 2006 | 786 | 0.240 |
Why?
|
Mycobacterium Infections | 1 | 2004 | 13 | 0.230 |
Why?
|
United States | 8 | 2022 | 7367 | 0.230 |
Why?
|
Kidney Diseases | 1 | 2006 | 307 | 0.230 |
Why?
|
Evaluation Studies as Topic | 8 | 1998 | 219 | 0.230 |
Why?
|
Chlamydia trachomatis | 1 | 2003 | 26 | 0.220 |
Why?
|
Antibodies, Viral | 2 | 2022 | 110 | 0.220 |
Why?
|
Neisseria gonorrhoeae | 1 | 2003 | 35 | 0.220 |
Why?
|
Chlamydia Infections | 1 | 2003 | 41 | 0.220 |
Why?
|
Nocardia | 2 | 1993 | 6 | 0.220 |
Why?
|
Gonorrhea | 1 | 2003 | 50 | 0.220 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2006 | 627 | 0.220 |
Why?
|
Mycobacterium tuberculosis | 3 | 1995 | 103 | 0.220 |
Why?
|
Enterococcus | 2 | 2020 | 29 | 0.210 |
Why?
|
Antigens, Bacterial | 2 | 2016 | 54 | 0.200 |
Why?
|
Prevalence | 3 | 2016 | 1619 | 0.190 |
Why?
|
Sepsis | 2 | 2018 | 233 | 0.190 |
Why?
|
Encephalitis | 2 | 2003 | 43 | 0.190 |
Why?
|
Enterococcus faecalis | 2 | 2008 | 6 | 0.190 |
Why?
|
Child | 6 | 2017 | 6405 | 0.190 |
Why?
|
Immunoglobulin G | 2 | 2020 | 481 | 0.180 |
Why?
|
Interferon-alpha | 1 | 2000 | 46 | 0.180 |
Why?
|
Gram-Positive Bacteria | 1 | 2020 | 23 | 0.180 |
Why?
|
Candidiasis | 2 | 1997 | 39 | 0.180 |
Why?
|
Staphylococcus | 1 | 2020 | 29 | 0.180 |
Why?
|
Microfluidics | 1 | 2020 | 22 | 0.180 |
Why?
|
Gram-Positive Bacterial Infections | 2 | 1997 | 35 | 0.170 |
Why?
|
Vancomycin | 2 | 1997 | 60 | 0.170 |
Why?
|
Cerebrospinal Fluid | 2 | 2010 | 23 | 0.160 |
Why?
|
Leadership | 1 | 2020 | 136 | 0.160 |
Why?
|
Algorithms | 3 | 2020 | 1196 | 0.160 |
Why?
|
Antiviral Agents | 1 | 2000 | 211 | 0.160 |
Why?
|
Luminescent Measurements | 1 | 2018 | 58 | 0.160 |
Why?
|
Molecular Probe Techniques | 1 | 1998 | 7 | 0.160 |
Why?
|
Antifungal Agents | 2 | 2007 | 108 | 0.150 |
Why?
|
Cross Infection | 3 | 2009 | 195 | 0.150 |
Why?
|
DNA, Bacterial | 4 | 2012 | 150 | 0.150 |
Why?
|
Societies, Medical | 1 | 2020 | 403 | 0.150 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 306 | 0.150 |
Why?
|
Gene Amplification | 3 | 2004 | 71 | 0.150 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2017 | 11 | 0.140 |
Why?
|
Amphotericin B | 1 | 1997 | 26 | 0.140 |
Why?
|
Fluconazole | 1 | 1997 | 26 | 0.140 |
Why?
|
Treponema pallidum | 1 | 2016 | 5 | 0.140 |
Why?
|
Candida albicans | 1 | 1997 | 39 | 0.140 |
Why?
|
Gram-Positive Asporogenous Rods | 1 | 1996 | 1 | 0.140 |
Why?
|
Non-Randomized Controlled Trials as Topic | 1 | 2016 | 19 | 0.140 |
Why?
|
Syphilis | 1 | 2016 | 15 | 0.140 |
Why?
|
False Negative Reactions | 4 | 2016 | 63 | 0.140 |
Why?
|
Vibrio Infections | 1 | 1996 | 3 | 0.140 |
Why?
|
Mitosporic Fungi | 1 | 1996 | 2 | 0.140 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2016 | 9 | 0.140 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1997 | 70 | 0.140 |
Why?
|
Chromosome Deletion | 1 | 2016 | 41 | 0.140 |
Why?
|
Antibodies, Bacterial | 1 | 2016 | 90 | 0.140 |
Why?
|
Opportunistic Infections | 1 | 1996 | 33 | 0.130 |
Why?
|
Quality Control | 4 | 2021 | 81 | 0.130 |
Why?
|
Immunoassay | 2 | 2018 | 64 | 0.130 |
Why?
|
Immunoenzyme Techniques | 3 | 2016 | 196 | 0.130 |
Why?
|
Mycoses | 1 | 1996 | 60 | 0.130 |
Why?
|
Rhinovirus | 3 | 2017 | 15 | 0.130 |
Why?
|
Streptococcus pneumoniae | 1 | 1995 | 32 | 0.130 |
Why?
|
Poloxalene | 1 | 1995 | 2 | 0.130 |
Why?
|
DNA | 1 | 1998 | 597 | 0.120 |
Why?
|
Mycobacterium avium Complex | 1 | 1995 | 16 | 0.120 |
Why?
|
Sputum | 2 | 1993 | 51 | 0.120 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2013 | 618 | 0.120 |
Why?
|
Cervix Uteri | 1 | 2014 | 64 | 0.120 |
Why?
|
Cytomegalovirus Infections | 1 | 1995 | 69 | 0.120 |
Why?
|
Fungi | 2 | 2020 | 27 | 0.120 |
Why?
|
Virus Cultivation | 3 | 2009 | 3 | 0.110 |
Why?
|
Prospective Studies | 3 | 2016 | 3705 | 0.110 |
Why?
|
RNA, Messenger | 1 | 1998 | 1664 | 0.110 |
Why?
|
Parasitology | 1 | 2013 | 4 | 0.110 |
Why?
|
Gentamicins | 2 | 1993 | 68 | 0.110 |
Why?
|
Exudates and Transudates | 1 | 2013 | 25 | 0.110 |
Why?
|
Monitoring, Physiologic | 2 | 2000 | 219 | 0.110 |
Why?
|
Microscopy | 1 | 2013 | 64 | 0.110 |
Why?
|
Diagnostic Errors | 2 | 2008 | 100 | 0.110 |
Why?
|
Nocardia asteroides | 1 | 1992 | 4 | 0.110 |
Why?
|
DNA, Ribosomal | 1 | 2012 | 59 | 0.100 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2012 | 85 | 0.100 |
Why?
|
Molecular Sequence Data | 3 | 2005 | 1447 | 0.100 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 131 | 0.100 |
Why?
|
Regression Analysis | 2 | 2004 | 737 | 0.100 |
Why?
|
Anesthesia, Closed-Circuit | 1 | 1991 | 1 | 0.100 |
Why?
|
Water Microbiology | 3 | 2009 | 24 | 0.090 |
Why?
|
Prognosis | 2 | 2014 | 2093 | 0.090 |
Why?
|
Anesthesia, General | 1 | 1991 | 86 | 0.090 |
Why?
|
Cord Factors | 1 | 1990 | 1 | 0.090 |
Why?
|
Pregnancy | 2 | 2014 | 2334 | 0.090 |
Why?
|
Glycolipids | 1 | 1990 | 20 | 0.090 |
Why?
|
Bacteria | 2 | 2008 | 193 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2012 | 245 | 0.090 |
Why?
|
Early Detection of Cancer | 1 | 2014 | 454 | 0.080 |
Why?
|
Tuberculosis | 1 | 1990 | 77 | 0.080 |
Why?
|
Fluorescence | 2 | 2004 | 104 | 0.080 |
Why?
|
Legionella pneumophila | 1 | 2009 | 6 | 0.080 |
Why?
|
Ice | 1 | 2009 | 13 | 0.080 |
Why?
|
Latex Fixation Tests | 2 | 2005 | 4 | 0.080 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2008 | 44 | 0.080 |
Why?
|
Equipment Contamination | 1 | 2009 | 38 | 0.080 |
Why?
|
Klebsiella Infections | 1 | 2008 | 13 | 0.080 |
Why?
|
Medical Laboratory Personnel | 1 | 2008 | 1 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2009 | 37 | 0.080 |
Why?
|
Uncertainty | 1 | 2008 | 31 | 0.080 |
Why?
|
Antibodies, Heterophile | 1 | 2008 | 11 | 0.080 |
Why?
|
Disease Outbreaks | 1 | 2009 | 83 | 0.080 |
Why?
|
Liver Diseases | 2 | 2000 | 193 | 0.080 |
Why?
|
Candida | 2 | 1999 | 15 | 0.080 |
Why?
|
Blotting, Western | 1 | 2010 | 954 | 0.080 |
Why?
|
Vibrionaceae | 1 | 1988 | 1 | 0.080 |
Why?
|
Proctitis | 1 | 1988 | 2 | 0.080 |
Why?
|
DNA, Fungal | 2 | 1999 | 20 | 0.080 |
Why?
|
Daptomycin | 1 | 2008 | 11 | 0.080 |
Why?
|
Bronchoalveolar Lavage Fluid | 2 | 2009 | 117 | 0.080 |
Why?
|
Patient Care | 1 | 2008 | 61 | 0.080 |
Why?
|
Endocarditis, Bacterial | 1 | 2008 | 32 | 0.080 |
Why?
|
Specimen Handling | 2 | 2008 | 47 | 0.080 |
Why?
|
Yersinia | 1 | 1987 | 2 | 0.070 |
Why?
|
Yersinia Infections | 1 | 1987 | 2 | 0.070 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2007 | 21 | 0.070 |
Why?
|
Isoenzymes | 1 | 2008 | 308 | 0.070 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 177 | 0.070 |
Why?
|
Zygomycosis | 1 | 2007 | 3 | 0.070 |
Why?
|
Fungemia | 2 | 1997 | 13 | 0.070 |
Why?
|
Dermatomycoses | 1 | 2007 | 17 | 0.070 |
Why?
|
Drug Resistance, Bacterial | 1 | 2008 | 98 | 0.070 |
Why?
|
Meningitis | 1 | 2007 | 23 | 0.070 |
Why?
|
Triazoles | 1 | 2007 | 43 | 0.070 |
Why?
|
Fluorescent Dyes | 2 | 2006 | 191 | 0.070 |
Why?
|
BK Virus | 1 | 2006 | 17 | 0.070 |
Why?
|
Drug Resistance, Microbial | 3 | 1997 | 70 | 0.070 |
Why?
|
Cytochrome P-450 CYP2C9 | 1 | 2006 | 5 | 0.070 |
Why?
|
Transition Temperature | 1 | 2006 | 9 | 0.070 |
Why?
|
Treatment Outcome | 2 | 2016 | 7029 | 0.070 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 1986 | 21 | 0.070 |
Why?
|
Alleles | 2 | 2006 | 386 | 0.070 |
Why?
|
Enterobacteriaceae | 1 | 1985 | 29 | 0.070 |
Why?
|
Viral Proteins | 1 | 2007 | 150 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2005 | 35 | 0.060 |
Why?
|
Warfarin | 1 | 2006 | 93 | 0.060 |
Why?
|
Epitopes | 1 | 1986 | 146 | 0.060 |
Why?
|
Base Sequence | 3 | 2003 | 1015 | 0.060 |
Why?
|
Resins, Plant | 1 | 1984 | 4 | 0.060 |
Why?
|
Animals | 6 | 2003 | 20881 | 0.060 |
Why?
|
Serotyping | 3 | 2009 | 16 | 0.060 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2005 | 92 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2006 | 504 | 0.060 |
Why?
|
Hydrotherapy | 1 | 2004 | 1 | 0.060 |
Why?
|
Oligonucleotides | 1 | 2004 | 34 | 0.060 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 2004 | 23 | 0.060 |
Why?
|
Open Reading Frames | 1 | 2004 | 25 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2000 | 1745 | 0.060 |
Why?
|
Acanthamoeba | 1 | 2003 | 2 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 10 | 0.060 |
Why?
|
Amebiasis | 1 | 2003 | 6 | 0.060 |
Why?
|
Tracheostomy | 1 | 2003 | 31 | 0.060 |
Why?
|
Urine | 1 | 2003 | 47 | 0.060 |
Why?
|
Coronavirus | 2 | 2017 | 16 | 0.060 |
Why?
|
Anticoagulants | 1 | 2006 | 356 | 0.060 |
Why?
|
Automation | 1 | 2003 | 45 | 0.050 |
Why?
|
Viral Nonstructural Proteins | 1 | 2003 | 16 | 0.050 |
Why?
|
Plasmids | 1 | 1984 | 258 | 0.050 |
Why?
|
Charcoal | 2 | 1993 | 37 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2008 | 711 | 0.050 |
Why?
|
Fatal Outcome | 2 | 2008 | 164 | 0.050 |
Why?
|
DNA Probes | 2 | 1999 | 57 | 0.050 |
Why?
|
Serologic Tests | 1 | 2022 | 46 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 507 | 0.050 |
Why?
|
Wound Healing | 1 | 2003 | 260 | 0.050 |
Why?
|
Practice Guidelines as Topic | 3 | 2000 | 772 | 0.050 |
Why?
|
Plasma | 2 | 2006 | 58 | 0.050 |
Why?
|
Hepatitis, Viral, Human | 1 | 2000 | 7 | 0.050 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2020 | 20 | 0.050 |
Why?
|
Species Specificity | 4 | 1999 | 303 | 0.050 |
Why?
|
Artificial Intelligence | 1 | 2022 | 159 | 0.050 |
Why?
|
Public Health | 1 | 2022 | 201 | 0.040 |
Why?
|
Peptides | 1 | 2003 | 455 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 144 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2020 | 7277 | 0.040 |
Why?
|
Biomarkers | 3 | 2018 | 1593 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 1999 | 98 | 0.040 |
Why?
|
Phosphoproteins | 1 | 2020 | 202 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2000 | 567 | 0.040 |
Why?
|
Limit of Detection | 1 | 2018 | 11 | 0.040 |
Why?
|
DNA Primers | 2 | 1997 | 302 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2000 | 742 | 0.040 |
Why?
|
Antimicrobial Stewardship | 1 | 2018 | 33 | 0.040 |
Why?
|
Flaviviridae | 1 | 1998 | 2 | 0.040 |
Why?
|
Anti-HIV Agents | 1 | 1999 | 135 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 1998 | 23 | 0.040 |
Why?
|
Carbon-Oxygen Ligases | 1 | 1997 | 1 | 0.040 |
Why?
|
Ligases | 1 | 1997 | 6 | 0.040 |
Why?
|
Trypanosoma brucei brucei | 1 | 1998 | 20 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2018 | 109 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 1998 | 63 | 0.040 |
Why?
|
Radiometry | 2 | 1990 | 64 | 0.040 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2017 | 11 | 0.040 |
Why?
|
Forensic Pathology | 1 | 2017 | 19 | 0.040 |
Why?
|
Flucytosine | 1 | 1997 | 5 | 0.040 |
Why?
|
Syphilis Serodiagnosis | 1 | 2016 | 6 | 0.040 |
Why?
|
Virulence | 1 | 1997 | 51 | 0.040 |
Why?
|
Drug Resistance, Multiple | 1 | 1997 | 56 | 0.040 |
Why?
|
Cellulitis | 1 | 1996 | 13 | 0.030 |
Why?
|
Bacterial Typing Techniques | 1 | 1996 | 19 | 0.030 |
Why?
|
Eels | 1 | 1996 | 2 | 0.030 |
Why?
|
Vibrio | 1 | 1996 | 14 | 0.030 |
Why?
|
Food Microbiology | 1 | 1996 | 24 | 0.030 |
Why?
|
Adenoviridae | 1 | 2017 | 295 | 0.030 |
Why?
|
Hepatitis, Chronic | 1 | 1995 | 3 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 1996 | 242 | 0.030 |
Why?
|
Immunologic Techniques | 1 | 1995 | 30 | 0.030 |
Why?
|
Necrosis | 1 | 1996 | 239 | 0.030 |
Why?
|
Ganciclovir | 1 | 1995 | 27 | 0.030 |
Why?
|
Genetic Techniques | 1 | 1995 | 32 | 0.030 |
Why?
|
Leukocytes | 1 | 1995 | 99 | 0.030 |
Why?
|
Cohort Studies | 1 | 2020 | 2358 | 0.030 |
Why?
|
Rifampin | 1 | 1995 | 45 | 0.030 |
Why?
|
Campylobacter | 1 | 1994 | 5 | 0.030 |
Why?
|
Drug Synergism | 1 | 1995 | 260 | 0.030 |
Why?
|
South Carolina | 1 | 2020 | 2752 | 0.030 |
Why?
|
Forecasting | 1 | 1995 | 277 | 0.030 |
Why?
|
Buffers | 1 | 1993 | 31 | 0.030 |
Why?
|
Streptomycin | 1 | 1993 | 12 | 0.030 |
Why?
|
Enterobacteriaceae Infections | 1 | 1993 | 25 | 0.030 |
Why?
|
Carbon Dioxide | 1 | 1993 | 78 | 0.030 |
Why?
|
Yeast, Dried | 1 | 1992 | 1 | 0.030 |
Why?
|
Escherichia coli | 1 | 1994 | 368 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 1994 | 562 | 0.020 |
Why?
|
Micrococcus | 1 | 1991 | 4 | 0.020 |
Why?
|
Staphylococcal Infections | 1 | 1993 | 156 | 0.020 |
Why?
|
Filtration | 1 | 1991 | 61 | 0.020 |
Why?
|
MEDLINE | 2 | 2000 | 9 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1991 | 193 | 0.020 |
Why?
|
Liver Function Tests | 2 | 2000 | 114 | 0.020 |
Why?
|
Cost Control | 1 | 1989 | 34 | 0.020 |
Why?
|
Equipment Design | 1 | 1991 | 500 | 0.020 |
Why?
|
Disease Reservoirs | 1 | 2009 | 7 | 0.020 |
Why?
|
Bronchoscopes | 1 | 2009 | 9 | 0.020 |
Why?
|
Metapneumovirus | 1 | 2009 | 1 | 0.020 |
Why?
|
Acute Disease | 2 | 2000 | 658 | 0.020 |
Why?
|
Hematologic Tests | 1 | 2008 | 24 | 0.020 |
Why?
|
Time | 1 | 2008 | 57 | 0.020 |
Why?
|
Efficiency, Organizational | 1 | 2008 | 61 | 0.020 |
Why?
|
Bisexuality | 1 | 1988 | 18 | 0.020 |
Why?
|
Coagulase | 1 | 1986 | 14 | 0.020 |
Why?
|
Staphylococcal Protein A | 1 | 1986 | 15 | 0.020 |
Why?
|
Immunodiffusion | 1 | 1986 | 19 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 1986 | 511 | 0.020 |
Why?
|
Heart Valve Prosthesis | 1 | 1988 | 222 | 0.020 |
Why?
|
Aortic Valve | 1 | 1988 | 249 | 0.020 |
Why?
|
Lymphoproliferative Disorders | 1 | 2006 | 37 | 0.020 |
Why?
|
Chronic Disease | 2 | 2000 | 1330 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 272 | 0.020 |
Why?
|
Hepatitis C Antibodies | 1 | 2005 | 19 | 0.020 |
Why?
|
Genes, Bacterial | 1 | 1985 | 40 | 0.020 |
Why?
|
Enzymes | 1 | 1985 | 25 | 0.020 |
Why?
|
Genes | 1 | 1985 | 86 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2005 | 137 | 0.020 |
Why?
|
Length of Stay | 1 | 2008 | 780 | 0.020 |
Why?
|
Blood Cells | 1 | 1984 | 27 | 0.020 |
Why?
|
Mice | 1 | 1997 | 8474 | 0.020 |
Why?
|
Organ Transplantation | 1 | 2006 | 110 | 0.020 |
Why?
|
Granulation Tissue | 1 | 2003 | 6 | 0.010 |
Why?
|
Tracheal Stenosis | 1 | 2003 | 21 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2003 | 38 | 0.010 |
Why?
|
Adsorption | 1 | 1984 | 225 | 0.010 |
Why?
|
Cicatrix | 1 | 2003 | 60 | 0.010 |
Why?
|
Peptide Library | 1 | 2003 | 16 | 0.010 |
Why?
|
Organ Specificity | 1 | 2003 | 167 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2003 | 357 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 1046 | 0.010 |
Why?
|
Leucyl Aminopeptidase | 1 | 1982 | 1 | 0.010 |
Why?
|
Esterases | 1 | 1982 | 9 | 0.010 |
Why?
|
Acid Phosphatase | 1 | 1982 | 36 | 0.010 |
Why?
|
Methods | 1 | 1982 | 156 | 0.010 |
Why?
|
Alkaline Phosphatase | 1 | 1982 | 71 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2003 | 852 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2007 | 694 | 0.010 |
Why?
|
Sex Factors | 1 | 2003 | 1266 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1984 | 2673 | 0.010 |
Why?
|
Phosphodiesterase I | 1 | 1999 | 3 | 0.010 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 1999 | 22 | 0.010 |
Why?
|
Age Factors | 1 | 2003 | 1864 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2006 | 1615 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2003 | 3259 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2003 | 778 | 0.010 |
Why?
|
Risk Factors | 1 | 2005 | 5731 | 0.010 |
Why?
|
Phenotype | 1 | 1997 | 947 | 0.010 |
Why?
|
Genetic Variation | 1 | 1985 | 220 | 0.000 |
Why?
|